- Home
- EXEL vs HMY Comparison
EXEL vs HMY Comparison
Compare EXEL & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | HMY |
|---|---|---|
| Founded | 1994 | 1950 |
| Country | United States | South Africa |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 13.1B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | HMY |
|---|---|---|
| Price | $43.96 | $21.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $46.60 | $16.00 |
| AVG Volume (30 Days) | 2.6M | ★ 5.3M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.66 | $39.29 |
| Revenue Next Year | $14.30 | $22.99 |
| P/E Ratio | $15.69 | ★ $15.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.38 | $9.69 |
| 52 Week High | $48.74 | $26.04 |
Technical Indicators
Market Signals| Indicator | EXEL | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 52.94 |
| Support Level | $42.57 | $14.09 |
| Resistance Level | $44.15 | $21.83 |
| Average True Range (ATR) | 1.30 | 0.98 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 80.53 | 88.79 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.